Mechanistic, translational, quantitative pain assessment tools in profiling of pain patients and for development of new analgesic compounds

Scandinavian Journal of Pain

Volumn 4, Issue 4, 2013, Pages 226-230

  Arendt Nielsen, Lars ^a   Curatolo, Michele ^b  

^a AALBORG UNIVERSITY   (Denmark)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Assessment of pain; Chronic pain; Drug development; Drug profiling; Proof of concept; Volunteers

Indexed keywords

BOTULINUM TOXIN; OMEGA CONOTOXIN MVIIA; PF 592379; TANEZUMAB; TAPENTADOL;

ALLODYNIA; CHRONIC PAIN; CLINICAL ASSESSMENT TOOL; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG ANALYSIS; DRUG SCREENING; HUMAN; HYPERALGESIA; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH;

EID: 84885389951     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2013.07.026     Document Type: Review

References (41)

1. Sindrup S.H., Finnerup N.B., Jensen T.S. Tailored treatment of peripheral neuropathic pain. Pain 2012, 153:1781-1782.
2. Breivik H., Collett B., Ventafridda V., Cohen R., Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006, 10:287-333.
3. Robinson I., Dowdall T., Meert T.F. Development of neuropathic pain is affected by bedding texture in two models of peripheral nerve injury in rats. Neurosci Lett 2004, 368:107-111.
4. Christoph T., Kogel B., Schiene K., Méen M., De Vry J., Friderichs E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005, 507:87-98.
5. Kontinen V.K., Meert T.F. Predictive validity of neuropathic pain models in pharmacological studies with a behavioral outcome in the rat: a systematic review. 10th World Congress on Pain 2003, 489-498. IASP Press, San Diego. J. Dostrovsky, D.B. Carr, M. Koltzenburg (Eds.).
6. Quessy S.N. The challenges of translational research for analgesics: the state of knowledge needs upgrading and some uncomfortable deficiencies remain to be urgently addressed. J Pain 2010, 11:698-700.
7. Mao J. Translational pain research: achievements and challenges. J Pain 2009, 10:1001-1011.
8. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011, 10:328-329.
9. Rice A.S., Cimino-Brown D., Eisenach J.C., Kontinen V.K., Lacroix-Fralish M.L., Machin I. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 2008, 139:243-247.
10. Kissin I. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg 2010, 110:780-789.
11. Dray A. Neuropathic pain: emerging treatments. Br J Anaesth 2008, 101:48-58.
12. Arendt-Nielsen L., Yarnitsky D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain 2009, 10:556-572.
13. Arendt-Nielsen L., Hoeck H.C. Optimizing the early phase development of new analgesics by human pain biomarkers. Expert Rev Neurother 2011, 11:1631-1651.
14. Woolf C.J. Overcoming obstacles to developing new analgesics. Nat Med 2010, 16:1241-1247.
15. Graven-Nielsen T., Arendt-Nielsen L. Assessment of mechanisms in localized and widespread musculoskeletal pain. Nat Rev Rheumatol 2010, 6:599-606.
16. Klein T., Magerl W., Rolke R. Human surrogate models of neuropathic pain. Pain 2005, 115:227-233.
17. Fimer I., Klein T., Magerl W. Modality-specific somatosensory changes in a human surrogate model of postoperative pain. Anesthesiology 2011, 115:387-397.
18. Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009, 89:707-758.
19. Staahl C., Olesen A.E., Andresen T., Arendt-Nielsen L., Drewes A.M. Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers: an updated review. Br J Clin Pharmacol 2009, 68:322-341.
20. Staahl C., Olesen A.E., Andresen T., Arendt-Nielsen L., Drewes A.M. Assessing analgesic actions of opioids by experimental pain models in healthy volunteers - an updated review. Br J Clin Pharmacol 2009, 68:149-168.
21. Brock C., Arendt-Nielsen L., Wilder-Smith O., Drewes A.M. Sensory testing of the human gastrointestinal tract. World J Gastroenterol 2009, 15:151-159.
22. Wise R.G., Tracey I. The role of fMRI in drug discovery. J Magn Reson Imaging 2006, 23:862-876.
23. Maier C., Baron R., Tölle T.R., Binder A., Birbaumer N., Birklein F., Gierthmühlen J., Flor H., Geber C., Huge V., Krumova E.K., Landwehrmeyer G.B., Magerl W., Maihöfner C., Richter H., Rolke R., Scherens A., Schwarz A., Sommer C., Tronnier V., Uçeyler N., Valet M., Wasner G., Treede R.D. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 2010, 150:439-450.
24. Arendt-Nielsen L., Graven-Nielsen T. Translational musculoskeletal pain research. Best Pract Res Clin Rheumatol 2011, 25:209-226.
25. Morgan P., Van Der Graaf P.H., Arrowsmith J., Feltner D.E., Drummond K.S., Wegner C.D., Street S.D. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 2012, 17:419-424.
26. Wei H., Viisanen H., Pertovaara A. Descending modulation of neuropathic hypersensitivity by dopamine D2 receptors in or adjacent to the hypothalamic A11 cell group. Pharmacol Res 2009, 59:355-363.
27. Oono Y., Nie H., Matos R.V.L., Wang K., Arendt-Nielsen L. The inter- and intra-individual variance in descending pain modulation evoked by different conditioning stimuli in healthy men. Scand J Pain 2011, 2:162-169.
28. Arendt-Nielsen L., Nie H., Laursen M.B., Laursen B.S., Madeleine P., Simonsen O.H., Graven-Nielsen T. Sensitization in patients with painful knee osteoarthritis. Pain. 2010, 149:573-581.
29. Chizh B.A., Sang C.N. Use of sensory methods for detecting target engagement in clinical trials of new analgesics. Neurotherapeutics 2009, 6:749-754.
30. Chizh B.A., O'Donnell M.B., Napolitano A., Wang J., Brooke A.C., Aylott M.C., Bullman J.N., Gray E.J., Lai R.Y., Williams P.M., Appleby J.M. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007, 132:132-141.
31. Freund B., Schwartz M. Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A. J Pain 2003, 4:159-165.
32. Bach-Rojecky L., Relja M., Lackovic Z. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm 2005, 112:215-219.
33. Gazerani P., Staahl C., Drewes A.M., Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006, 122:315-325.
34. Gazerani P., Pedersen N.S., Staahl C., Drewes A.M., Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141:60-69.
35. Staahl C., Christrup L.L., Andersen S.D., Arendt-Nielsen L., Drewes A.M. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006, 123:28-36.
36. Staahl C., Dimcevski G., Andersen S.D., Thorsgaard N., Christrup L.L., Arendt-Nielsen L., Drewes A.M. Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study. Scand J Gastroenterol 2007, 42:383-390.
37. Koppert W., Ihmsen H., Körber N., Wehrfritz A., Sittl R., Schmelz M., Schüttler J. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005, 118:15-22.
38. Koivisto A., Pertovaara A. Transient receptor potential ankyrin 1 (TRPA1) ion channel in the pathophysiology of peripheral diabetic neuropathy. Scand J Pain 2013, 4:129-136.
39. Jensen T.S. New understanding of mechanisms of painful diabetic neuropathy: a path to prevention and better treatment?. Scand J Pain 2013, 4:127-128.
40. Rice A.S.C., Morland R., Huang W., Currie G.L., Sena E.S., Macleod M.R. Transparency in the reporting of in vivo pre-clinical pain research: the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines. Scand J Pain 2013, 4:58-62.
41. Kontinen V. From clear reporting to better research models. Scand J Pain 2013, 4:57.